About us Leadership History News Clinical Trials Publications Contact us News & events Press Releases View all November 16, 2021 Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe Read more November 2, 2021 Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform October 7, 2021 Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy In the news View all September 14, 2021 1st JCA-AACR Precision Cancer Medicine International Conference July 20, 2021 Journal of Clinical Oncology, An American Society of Clinical Oncology Journal June 10, 2021 AACR Journal of Cancer Research Proceedings Get to Know Us March 23, 2021 Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC) July 9, 2020 Unconventional Weapon in the War on Cancer Revealed June 10, 2019 Immunicom Announces First Patient Enrollment in Multi-Center, Triple-Negative Breast Cancer Clinical Trial May 14, 2018 Immunicom’s Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer Get in touch today Let’s talk about what we can achieve together Contact us Learn more about our team Who are we Immunicom Inc. HEADQUARTERS San Diego, CA RESOURCES Terms of Use Privacy policy GET IN TOUCH Contact us Newsletter Subscription Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. © 2021 — Immunicom, Inc. All Rights Reserved. We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics. Cookie settings Accept all